Key result
Review summarizes recent evidence on reduced-dose DOACs for secondary VTE prevention.
Why the study?
Do reduced-dose DOACs improve outcomes in secondary prevention of venous thromboembolism?
Do reduced-dose DOACs improve outcomes in secondary prevention of venous thromboembolism?
This article interprets the latest evidence regarding the use of reduced-dose DOACs for the secondary prevention of venous thromboembolism.
Answers are grounded in this paper and cite their sources.
Should not yet change dosing practices; leaves open the need for dedicated RCTs in secondary VTE prevention.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kirollos Salah Kamel (2026) studied this question. The article reviews recent evidence on reduced-dose DOACs for secondary prevention of venous thromboembolism without presenting new data.
Synapse has enriched 10 related papers. Consider them for comparative context: